Menu
Search
|

Menu

Close
X

Medicines Co MDCO.OQ (NASDAQ Stock Exchange Global Select Market)

36.36 USD
-0.07 (-0.19%)
As of 6:21 PM BST
Previous Close 36.43
Open 36.80
Volume 157,793
3m Avg Volume 421,230
Today’s High 36.80
Today’s Low 35.74
52 Week High 41.33
52 Week Low 16.71
Shares Outstanding (mil) 72.64
Market Capitalization (mil) 2,772.65
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.54 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
6
FY17
81
FY16
143
EPS (USD)
FY19
-0.804
FY18
-3.196
FY17
-12.895
FY16
0.191
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
26.22
7.92
Price to Book (MRQ)
vs sector
13.51
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
310.31
14.56
LT Debt to Equity (MRQ)
vs sector
149.03
10.21
Return on Investment (TTM)
vs sector
-62.66
14.49
Return on Equity (TTM)
vs sector
-137.15
15.79

EXECUTIVE LEADERSHIP

Mark Timney
Chief Executive Officer, Director, Since 2018
Salary: $36,538.00
Bonus: $50,000.00
Christopher Visioli
Chief Financial Officer, Treasurer, Since 2018
Salary: $375,000.00
Bonus: --
Stephen Rodin
General Counsel, Secretary, Since 2014
Salary: $453,625.00
Bonus: --
Clive Meanwell
Chief Innovation Officer, Since 2018
Salary: $750,149.00
Bonus: --
Alexander Denner
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

8 SYLVAN WAY
PARSIPPANY   NJ   07054

Phone: +1973.2906000

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

SPONSORED STORIES